Briat, Arnaud
Jacques, Claire
Malige, Mélodie
Sudre, Laure
Nourissat, Geoffroy
Auzeloux, Philippe
Guehring, Hans
Cachin, Florent
Berenbaum, Francis
Miot-Noirault, Elisabeth
Article History
Received: 19 November 2021
Accepted: 13 April 2022
First Online: 17 May 2022
Competing interests
: FB reports personal fees from Nordic Bioscience, during the conduct of the study (chair of DSMB for sprifermin NCT01919164); personal fees from Boehringer, Bone Therapeutics, CellProthera, Galapagos, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Peptinov, 4Moving Biotech, 4P Pharma, grants from TRB Chemedica, outside the submitted work. Other authors declare no conflict of interests.